HCPLive Network

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.


Further Reading
Scientists in the United Kingdom recently uncovered a new ‘family’ of drugs called padRAF inhibitors that are effective in treating melanoma patients who are resistant to BRAF inhibitors.
Researchers from the University of Missouri recently published study results indicating testosterone may play an integral role within colon cancer tumor formation.
Different brands of FITs with the same cutoff hemoglobin concentration have been reported to perform differently in detection of colorectal cancer (CRC).
More Reading